Lemtrada (Alemtuzumab)

Alemtuzumab binds to the CD52 antigen on mature T and B lymphocytes, triggering antibody‑dependent cellular cytotoxicity and complement‑mediated lysis. This results in rapid depletion of circulating lymphocytes, followed by immune reconstitution that reduces the autoreactive immune response responsible for multiple sclerosis attacks.

The dosing regimen for Lemtrada is determined by the prescribing physician based on the patient’s clinical condition, body weight and regulatory guidelines. Specific dose amounts, infusion rates and treatment intervals are individualized and should be obtained from the treating neurologist or specialist.

Lemtrada is classified as Pregnancy Category C, indicating that risk to the fetus cannot be ruled out. It is generally recommended to avoid use during pregnancy and to discontinue treatment before conception if possible. Breastfeeding is not advised while receiving alemtuzumab because the drug may be excreted in milk.

To order Lemtrada, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the team provides pricing, availability, cold‑chain shipping details and any necessary import documentation.

The principal alternatives for relapsing‑remitting multiple sclerosis include other monoclonal antibodies such as ocrelizumab and natalizumab. Compared with ocrelizumab, alemtuzumab induces a deeper, though transient, lymphocyte depletion and may offer longer intervals between dosing. Natalizumab works by blocking cell adhesion rather than depleting lymphocytes, and carries a different risk profile, notably a higher association with progressive multifocal leukoencephalopathy.

Lemtrada must be stored refrigerated at 2 °C to 8 °C. The product should be kept in its original packaging, protected from light, and must never be frozen or shaken. Prior to infusion, the solution is inspected for particulate matter and may be gently mixed if required, following the manufacturer’s instructions.

Lemtrada is administered as an intravenous infusion in a clinical setting. The initial course typically consists of two treatment cycles given on separate days, followed by additional courses at defined intervals, each lasting several hours. Infusion rates are gradually increased under medical supervision, and patients are monitored for infusion‑related reactions throughout the procedure.

Serious risks include the development of autoimmune disorders such as thyroid disease, immune thrombocytopenic purpura, and nephropathies; severe infections including opportunistic pathogens; and an increased incidence of certain malignancies, notably thyroid cancer. Patients should undergo regular laboratory monitoring and clinical assessment to detect these conditions early.

Lemtrada is contraindicated in individuals with known hypersensitivity to alemtuzumab or any of its excipients, in patients with active infections, and in those who are pregnant or planning pregnancy without appropriate contraception. Caution is also advised for patients with a history of autoimmune disease, severe cardiac or pulmonary conditions, or those receiving other potent immunosuppressive agents.